Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) for the year ending December 31, 2022: -17.52%

Cyteir Therapeutics Inc Current Liabilities to Total Liabilities Ratio 1 year YoY Change (%) is -17.52% for the year ending December 31, 2022, a -101.01% change year over year. The current liabilities to total liabilities ratio measures the proportion of a company's current liabilities in relation to its total liabilities. It is calculated by dividing current liabilities by total liabilities. This ratio provides insights into the percentage of a company's total liabilities that are classified as current liabilities. It helps evaluate the company's overall liability structure and the importance of short-term obligations in relation to total liabilities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Cyteir Therapeutics Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2022 was 0.77, a -17.52% change year over year.
  • Cyteir Therapeutics Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2021 was 0.93, a 1,726.68% change year over year.
  • Cyteir Therapeutics Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2020 was 0.05, a 53.77% change year over year.
  • Cyteir Therapeutics Inc Current Liabilities to Total Liabilities Ratio for the year ending December 31, 2019 was 0.03.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email